Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
1,783,394
-
Total 13F shares
-
14,345
-
Share change
-
+14,300
-
Total reported value
-
$207,858
-
Price per share
-
$14.49
-
Number of holders
-
8
-
Value change
-
+$207,206
-
Number of buys
-
7
Institutional Holders of Cadrenal Therapeutics, Inc. - Common Stock, par value $0.001 per share (CVKD) as of Q4 2024
As of 31 Dec 2024,
Cadrenal Therapeutics, Inc. - Common Stock, par value $0.001 per share (CVKD) was held by
8 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,345 shares.
The largest 9 holders included
GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, MORGAN STANLEY, OSAIC HOLDINGS, INC., Tower Research Capital LLC (TRC), R Squared Ltd, Archer Investment Corp, Carolina Wealth Advisors, LLC, and BANK OF AMERICA CORP /DE/.
This page lists
9
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.